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OBJECTIVE—Ghrelin and peptide YY (PYY) are both hormones
derived from the gastrointestinal tract involved in appetite regu-
lation. The cholinergic part of the vagal nerve is involved in the
regulation of glucose and insulin. The aim of this study was to
examine the effects of the cholinergic antagonist atropine on
ghrelin, PYY, glucose, and insulin under basal conditions and
after meal ingestion in lean and obese subjects.
REASEARCH DESIGN AND METHODS—Eight lean and eight
obese subjects were included in a randomized, double-blind,
placebo-controlled crossover study with 4 study days in random-
ized order (atropine/placebo  breakfast). Plasma ghrelin, PYY,
insulin, and glucose were measured. Hunger and satiety feelings
were rated on a 10-cm visual analog scale.
RESULTS—In lean individuals, atropine led to a decrease in
ghrelin concentrations comparable and nonadditive with break-
fast ingestion and a signiﬁcant decrease in both basal and
meal-induced PYY concentrations. In obese subjects, atropine
did not signiﬁcantly change ghrelin or PYY concentrations,
whereas it induced a comparable increase in heart rate and
meal-induced glucose concentrations in the two study groups.
Only lean, not obese, subjects experienced sustained feelings of
satiety after breakfast.
CONCLUSIONS—The impaired cholinergic regulation of the
postprandial drop in ghrelin concentrations and rise in PYY
concentrations might be part of the deregulated food intake in
obese subjects. Diabetes 57:2332–2340, 2008
E
nergy homeostasis is a tightly regulated process
involving hormone signaling from the periphery
via vagal afferents to the hindbrain (namely the
nucleus tractus solitarius) and the hypothala-
mus (especially the nucleus arcuatus), where these signals
are integrated with information from other brain regions
and processed to convey information to the periphery via
the sympathetic nervous system and the efferent part of
the vagal nerve (1,2). Peripheral organs sending and
receiving information to and from the brain include the
stomach and intestine, the pancreas, and the adipose
tissue (3). The latter has been a main focus of interest over
the last decade, driven by the discovery of leptin and
subsequently other adipokines (4). A renewed interest in
the regulation of appetite via a gut-brain interaction came
with new ﬁndings about two hormones: ghrelin and pep-
tide YY (PYY).
Ghrelin is the natural ligand of growth hormone secre-
tagogue receptor and is produced mainly in the stomach
(5). Although initially characterized as a potent growth
hormone, ghrelin was quickly discovered to also be a
potent orexigenic peptide (6). Ghrelin is involved in both
short- (7,8) and long-term (6,9) appetite regulation and
seems to exert its appetite-regulating effects mainly at the
hypothalamic level (10). Two hypothalamic regions have
been shown to be targeted by ghrelin, the arcuate nucleus
and the lateral hypothalamus. Food intake induced by
central administration of ghrelin has been shown to be
mediated via activating neuropeptide Y (NPY)/Agouti-
related protein (AGRP) neurons (11). Thus, ghrelin antag-
onizes the actions of leptin on the hypothalamus. On the
other hand, ghrelin has also been shown to interact with
the orexin pathway at the lateral hypothalamus (12).
PYY, named for the two tyrosine residues on the C- and
NH2-terminal termini of its 36–amino acid structure, is
produced by endocrine L-cells, mainly in the terminal
ileum and colon, and coexpressed in these cells with
glucagone-like peptide-1 (13). PYY levels rise after inges-
tion of a high-caloric meal (but before nutrients reach the
ileum) and remain elevated for at least 120 min (14). It has
been characterized as an agent inhibiting gastrointestinal
motility (15), but the anorexigenic effect of the active form
of PYY (3–36) has been shown only recently in humans
(16). Upon infusion of PYY (3–36), subsequent food con-
sumption was reduced in both lean and obese subjects
(17). Although a subsequent study challenged these initial
results (18) and other data suggested that this effect can
only be sustained by a carefully chosen intermittent infu-
sion scheme to prevent compensatory hyperphagia (19),
the fact that PYY is able to reduce caloric intake raised
hopes that a new antiobesity treatment could have been
found. PYY levels are reported to be reduced (17) or
unaltered (20) in obesity and increased in anorexia ner-
vosa (20).
Few data exist for the regulation of ghrelin and PYY
release from the gut. A main factor inﬂuencing ghrelin
plasma levels is food intake: shortly after oral glucose
load, ghrelin levels fall signiﬁcantly (21), whereas neither
gastric distension (6) nor rises in plasma glucose or insulin
levels alone (22) can suppress ghrelin release. Ghrelin
levels also rise anticipatory to meal initiation in both
humans (23) and sheep (24), and it has been suggested that
this rise is elicited centrally and mediated via the vagal
nerve to the stomach mucosa (24). In vagotomized rats,
baseline ghrelin levels and suppression of ghrelin levels by
nutrient load were unaltered, but an increase of ghrelin
levels induced by 48-h food deprivation was abolished
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2332 DIABETES, VOL. 57, SEPTEMBER 2008completely, and this result was mimicked by treatment
with the unspeciﬁc cholinergic antagonist atropine (25). In
a group of young healthy human volunteers, atropine
promptly and signiﬁcantly decreased ghrelin plasma con-
centrations after an overnight fast (26).
On the other hand, PYY increases after meal intake, with
a maximum reached after 1–2 h, dependent upon the
amount of calories ingested (27), particularly via fat (28).
Recent data indicate that increases in PYY in response to
meals is impaired in obesity (27,29). The time course of
PYY release (before nutrients reach the colon) suggests
neuronal control, and animal data show that an atropine-
sensitive cholinergic pathway is involved (30). To our
knowledge, the effect of atropine on PYY concentrations
has not been tested in humans.
In the study presented here, we addressed the following
questions: Does atropine decrease plasma ghrelin concen-
trations to the same amount as eating a standard meal? Is
this effect additive to meal induced ghrelin suppression? Is
there any correlation between atropine effects on heart
rate and ghrelin? How does atropine interact with PYY? Is
there any association with subjective ratings of hunger and
satiety? And, are there any different results in obese
subjects?
RESEARCH DESIGN AND METHODS
Eight obese (BMI 30 kg/m
2) and eight normal-weight control subjects (BMI
25 kg/m
2) were recruited from the obesity outpatient clinic and hospital
staff. All participants were nonsmokers, none of the control subjects were
taking any medication (with the exception of oral contraceptives), and one of
the obese subjects was on antidepressant and antihypertensive therapy. All
subjects underwent prestudy screening and had normal ﬁndings on laboratory
measurements, electrocardiogram, and physical examination. All subjects
underwent a 3-h oral glucose tolerance test (75 g glucose). The study protocol
was approved by the ethics committee of the Medical University of Vienna,
and all subjects gave informed consent before study entry.
The study was conducted with a prospective, randomized, single-blind,
placebo-controlled crossover design. For each subject, 4 study days (A–D)
were scheduled in randomized order with at least 3-day washout intervals. On
study days, subjects arrived between 8:00 and 11:00 A.M. after an overnight
fast. Studies were conducted in a quiet room with an ambient temperature of
22°C. Subjects abstained from alcohol and beverages containing caffeine 12 h
before the study days.
A plastic cannula (Venﬂon) was inserted into an antecubital vein at time
point 45 min. Blood samples were drawn at time points 30, 15, 0, 15,
30, 60, and 90 min for measurements of plasma ghrelin, PYY, insulin, and
glucose. At the same time points (plus time points 45 and 75 min), subjects
rated their hunger and satiety feelings on a 10-cm visual analog scale (VAS).
At time point 30, 1 mg atropine (atropimum sulfuricum, Nycomed; study
days A and B) or placebo (isotonic saline; study days C and D) was given
intravenously over 30 s. At time point 0, subjects received a standard breakfast
consisting of two rolls with 15 g butter and 250 ml milk with 10 g commercially
available cocoa mix (Benco, Suchard), total calorie content 590 kcal, total fat
content 23 g, total carbohydrate content 75 g, and total protein content 18.5 g,
on study days A and C only. Researchers and volunteers were blinded to
atropine/placebo dosage, and, until time point 0, to breakfast/no breakfast.
Blood pressure and pulse rate were monitored during the study period using
automated devices and recorded at time points 30, 29, 27, 25, 20,
15, 0, 15, 30, 45, 60, 75, and 90 min.
Laboratory monitoring. Samples for plasma hormone measurements were
centrifuged immediately at 4°C, and the supernatants were stored at 30°C
until analysis. Insulin levels (in micro units per milliliter) were assayed by a
commercially available RIA (Pharmacia-Upjohn, Uppsala, Sweden). Blood
glucose was determined according to standard laboratory procedures.
Plasma ghrelin (in pico grams per milliliter) was measured with a com-
mercial RIA (Peninsula Labs, San Carlos, CA) that uses I-125–labeled bioactive
ghrelin as a tracer and polyclonal antibody raised in rabbits against the
COOH-terminal end of human ghrelin. The inter- and intra-assay variations
were both 10.9%. PYY (in pico grams per milliliter) was measured using a
commercial RIA (Linco Research, St .Charles, MO) with inter- and intra-assay
variations of 8.2 and 9%, respectively.
Statistical analysis. Homeostasis model assessment (HOMA) model index
was calculated using HOMA calculator 2.2 (www.dtu.ox.ac.uk). Oral glucose
sensitivity index (OGIS) was calculated according to a previously published
formula (31) using the OGIS calculator (www.ladseb.pd.cnr.it/bioing/ogis/
home.html). Hormone concentrations at single time points and hormone
levels, heart rate, and VAS values at the 4 different study days were
compared with one-way ANOVA followed by multiple t tests with Bonferroni
correction as post hoc statistics, where appropriate. Baseline parameters and
heart rate response between the two groups were compared with unpaired
student’s t test. Linear regression analysis was performed to evaluate the
association (or lack of) between parameters, as indicated. SPSS statistical
software release 12.0.1 was used. P  0.05 was considered statistically
signiﬁcant. Results are presented as means  SEM.
RESULTS
Baseline characteristics of the subjects are shown in Table
1. The two groups were well matched for age, sex, and
height. Apart from having a signiﬁcantly higher BMI
(group-deﬁning criterion), obese subjects had signiﬁcantly
higher fasting glucose and insulin levels and were signiﬁ-
cantly more insulin resistant according to both HOMA and
OGIS indexes. Three obese subjects had impaired glucose
tolerance according to their 120-min glucose concentra-
tions (range 143–155 mg/dl).
Ghrelin. Ghrelin concentrations on the 4 study days are
given in Fig. 1. In control subjects, both atropine and meal
ingestion led to a decrease in ghrelin levels. There was a
signiﬁcant difference between ghrelin concentrations on
the different study days at time points 30, 60, and 90
min (as compared using one-way ANOVA). When compar-
ing differences between baseline and 90 min ghrelin
concentrations (ghrelin 30/90), values of the 3 study
days were signiﬁcantly different from the placebo day
without breakfast; the study days (A: atropine  breakfast,
B: atropine alone, and C: breakfast alone) did not differ
signiﬁcantly from each other (Fig. 1C).
In obese subjects, atropine had no effect on ghrelin
concentrations. When compared by ANOVA, ghrelin con-
centrations did not differ signiﬁcantly at any single time
point on the 4 different study days (Fig. 1B); when
comparing ghrelin 30/90 values, only breakfast had a
signiﬁcant effect on ghrelin concentrations (Fig. 1D).
PYY. PYY concentrations on the 4 study days are given in
Fig. 2. In the control group, atropine (study day B) led to
a signiﬁcant decrease of PYY concentrations at time point
90 min compared with breakfast alone (study day C).
Using 30/90 values (differences between baseline and
90 min PYY concentrations) atropine lead to a signiﬁcant
decrease of PYY concentrations compared with all other
study days, which did not differ signiﬁcantly from each
other (Fig 2C). In obese subjects, there were no signiﬁcant
TABLE 1
Baseline characteristics of study subjects
Lean Obese P
Age (years) 28.7  2.4 29.1  2.0 NS
Sex distribution (F/M) 6/2 6/2 NS
Height (cm) 173.6  3.5 169.1  4.0 NS
Weight (kg) 69.3  4.2 113.1  6.9 0.0001
BMI (kg/m
2) 22.9  1.0 39.6  2.2 0.0001
Waist-to-hip ratio 0.77  0.01 0.89  0.03 0.01
Fasting glucose (mg/dl) 83  2.1 94.4  2.6 0.005
Fasting insulin (U/ml) 10.5  1.5 20.3  3.2 0.021
HOMA 2.58  0.4 5.24  0.3 0.0001
OGIS 454.3  12.7 379.7  26.1 0.028
Data are means  SEM.
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points and between the 30/90 values (Fig. 2B and D,
respectively).
Heart rate, glucose, and insulin. Heart rates on the 4
study days are given in Fig. 3. Atropine led to a signiﬁcant
increase in heart rate in both obese and lean subjects
(baseline values, 72.0  3 min
1 control vs. 74.5  2 min
1
obese, P  0.5) with peak values at time point 25 min (5
min after atropine application, 100.3  7m i n
1 control vs.
97.8  2m i n
1 obese, P  0.7). Thus, heart rate increase
between baseline and time point 25 min (30/25)
was comparable in lean and obese subjects (23.25  1.8 vs.
28.25  5.8 min
1, P  0.42, by unpaired Student’s t test).
Plasma glucose and insulin concentrations are given in
Fig. 4. Atropine alone did not change plasma insulin or
glucose concentrations compared with placebo (study
days C and D). Meal-induced glucose increase was signif-
icantly affected by atropine only in obese subjects. Plasma
glucose in control subjects between study days A and B
were not signiﬁcantly different at any single time points, as
was the glucose difference between baseline and time
point 30 min (30/30) (10.8  4.5 vs. 1.8  1.2
mg/dl, P  0.178). Insulin concentrations between study
days A and B were signiﬁcantly different at time points
60 and 90 min, as was the difference between baseline
and time point 30 min (30/30) (23.3  9.4 vs. 2.2 
0.9 U/ml, P  0.003).
In obese subjects, atropine signiﬁcantly reduced meal-
induced blood glucose at time point 60 min (P  0.003).
Glucose difference between baseline and time point 30
min (30/30) was not signiﬁcantly different between
study days A and B (5.1  1.7 vs. 3.8  1.7 mg/dl, P 
0.18). Insulin levels were signiﬁcantly different between
study days A and B at time point 60 min (P  0.001). The
30/30 values were different between study days A and
B, but this difference did not reach statistical signiﬁcance
in the ANOVA analysis (23.3  9.4 vs. 0  0.4 U/ml, P 
0.133).
VAS. An overview of the time course of hunger and satiety
VAS is given in Fig. 5. Meal ingestion alone and in
combination with atropine led to sustained decreases in
hunger ratings and increases in satiety ratings in lean
individuals. Hunger scores tended to be lower and satiety
scores higher on atropine alone versus placebo days, yet
this difference did not reach statistical signiﬁcance in the
ANOVA analysis. When differences between baseline and
time point 90 (30/90) were compared (Fig. 5E),
both hunger and satiety 30/90 values for all breakfast
days were signiﬁcantly different from all days with no
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FIG. 1. Effect of atropine (Atr) (1 mg i.v. at time point 30 min) and breakfast (550 kcal at time point 0) on ghrelin plasma concentrations in
lean (control) and obese subjects. A and B: Plasma ghrelin concentrations in control (A) and obese (B) subjects on the 4 study days. Solid lines,
with breakfast; dotted lines, without breakfast; E, with atropine; , with placebo. C and D: Differences in baseline and postprandial ghrelin
concentrations (30/90) on the 4 study days in control (C) and obese (D) subjects. *Study days signiﬁcantly different from placebo day.
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cantly differ from each other.
In obese subjects, hunger ratings tended to be higher
and satiety ratings lower on atropine compared with
placebo days (Fig. 5B, again not statistically different for
any single time point in the ANOVA analysis). Hunger
scores on breakfast days started to slowly increase after
reaching a nadir value directly after meal ingestion. Con-
sequently, there were no statistical differences between
any of the study days in 30/90 values. When compar-
ing 30/90 values for satiety VAS, only study days B
and C differed signiﬁcantly from each other (P  0.012), all
other values were not statistically different from each
other (Fig. 5F).
Correlations. In lean subjects, there was a signiﬁcant
relationship between heart rate (30/25) and ghrelin
(30/90), as revealed by linear regression analysis (R
2 
0.373, P  0.0002, Fig. 6A). There was also a signiﬁcant
relationship between heart rate (30/25) and PYY
(30/90) (R
2  0.227, P  0.0058, Fig. 6C). In obese
subjects, there was no relationship between heart rate
(30/25) and ghrelin (30/90) (R
2  0.042, P  0.27,
Fig. 6B) and a weak but signiﬁcant relationship between
heart rate (30/25) and PYY (30/90) (R
2  0.136,
P  0.041, Fig. 6D).
In lean subjects, ghrelin (30/90) showed a signiﬁcant
correlation with VAS hunger (30/90) (R
2  0.178, P 
0.016, Fig. 6E), and PYY (30/90) correlated signiﬁcantly
with VAS satiety (30/90) (R
2  0.294, P  0.002, Fig.
6G), whereas there was no signiﬁcant correlation in obese
subjects (Fig. 6F and H, respectively). Insulin resistance as
quantiﬁed by HOMA and OGIS indexes was not signiﬁ-
cantly correlated with ghrelin and PYY changes induced by
atropine or breakfast (data not shown).
DISCUSSION
Several effects of ghrelin and PYY are conveyed by the
cholinergic autonomous nervous system, and signaling
from the gut to the brain is thought to be mediated in part
by cholinergic ﬁbers of the vagal nerve (32). We demon-
strate in this study that in lean healthy humans, ghrelin and
PYY release from the gut is also controlled by the cholin-
ergic system. Ghrelin concentrations are suppressed by
the unspeciﬁc muscarinic inhibitor atropine to the same
amount as by meal ingestion in a nonadditive manner, and
PYY release is signiﬁcantly reduced after atropine appli-
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mone release strongly correlates with the amount of heart
rate increase induced by atropine.
In contrast, in obese subjects, there was no clear
evidence of an inﬂuence of the cholinergic system on
ghrelin or PYY release. There were no signiﬁcant differ-
ences in hormone concentrations at any single time points
or in 30/90 values and only a weak association
between PYY and heart rate increase, whereas there was
no correlation between heart rate and ghrelin differences,
although all 4 study days were included in the regression
analysis to enhance data spreading. Despite this lack of
effect on gut hormone release, atropine-induced heart rate
increases in obese subjects was comparable with those in
lean subjects. The PYY data are somewhat limited by the
higher variability of baseline levels between study days,
and the correlation data are not as clear as those for
ghrelin. Nevertheless, our data show that not the response
to muscarinic inhibition per se but rather the cholinergic
control of orexigenic ghrelin and (to a lesser extent)
anorexic PYY release is disturbed in obesity. These results
are well in line with the large body of evidence showing
adrenergic sympathetic dysregulation of gut hormone, in
particular PYY release in obesity (33).
Parallel to the lack of cholinergic gut control, there was
also a disturbed sensing of hunger and satiety in response
to meals in the obese subjects compared with their lean
counterparts. VAS showed that the differences in hunger
ratings between baseline and postprandial states were not
statistically signiﬁcantly different between any study days
(although they tended to be lower on breakfast than on
nonbreakfast days), whereas lean subjects reported a
sustained suppression of hunger feelings at the end of the
study period (90 min after breakfast) on breakfast com-
pared with nonbreakfast days. To a lesser extent, the same
could be observed for ratings of satiety, with statistically
signiﬁcant differences between all breakfast versus non-
breakfast days in lean and ratings being only different
between study days B (atropine alone) and C (breakfast
alone) in obese subjects (although they also tended to be
lower on the other breakfast day than on nonbreakfast
days). Moreover, in lean subjects, there was a correlation
between 30/90 values for hunger ratings and ghrelin
and satiety ratings and PYY, respectively (as would be
expected when all 4 study days are included in the
analysis), but surprisingly again there was a complete lack
of association in obese subjects.
Actually, only part of the circulating ghrelin seems to be
associated with feelings of appetite, namely the active
(acylated) ghrelin, which in circulation becomes rapidly
degraded and inactive. Thus, since we measured only total
(acylated plus deacylated) ghrelin, our results relate
mainly to changes in ghrelin release, and the extension to
feelings of hunger and satiety must be regarded with
caution. It is possible that differences in ghrelin deacyla-
tion between lean and obese subjects rather than differ-
ences in ghrelin release were responsible for the observed
lack of correlation in obese subjects. Nonetheless, ghrelin
release—as shown by the changes in the surrogate param-
eter total ghrelin—seems to be remarkably different in
lean and obese subjects.
It has been proposed that the blunted ghrelin response
to meal ingestion could be responsible for the develop-
ment of obesity in adolescents (34). Whereas in the
absence of prospective data it is impossible to determine
whether this blunted hormone response is cause or con-
sequence of the disturbed eating behavior in obese sub-
jects, it has been shown that improved sensing of meal-
induced hunger suppression is associated with increased
postprandial ghrelin drop in subjects losing weight (35).
Similarly, it is impossible to know whether the disturbed
cholinergic gut hormone regulation was present before the
subjects studied here became obese or whether the dereg-
ulation of the system developed as a consequence of
overeating. Even if cholinergic regulation was the primary
factor in gut hormone release, feelings of hunger and
satiety are of course not solely driven by changes in gut
hormone levels alone: Although atropine caused a compa-
rable drop in ghrelin levels and an increase in PYY levels
as breakfast ingestion, there was no accompanying drop in
hunger or increase in satiety ratings in lean subjects. Yet,
even if a disturbed hormone regulation would lead to only
a slight impairment in sensing of hunger and satiety,
resulting in a small but daily additional calorie intake, this
would ultimately considerably contribute to weight gain in
the long term.
To our knowledge, there are no prospective data on the
involvement of either gut hormone alterations or impair-
ment of autonomic regulation in the etiology of obesity,
and although it seems clear by now that the ample
availability of energy dense food is part of the epidemic, it
is currently unclear why some people contract obesity
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some data to support the hypothesis of cholinergic path-
ways being a crucial part of appetite regulation: M3
muscarinic receptor knockout mice are reported to be
hypophagic and lean compared with their wild-type litter-
mates (36). The M3 receptor is expressed in the lateral
hypothalamus, and the melanin-concentrating hormone
(MCH)-containing neurons of this area are apparently
responsible for the M3 knockout phenotype. Interestingly,
these same neurons also receive projections from AGRP/
NPY neurons in the medial hypothalamus (37) (where
ghrelin exerts its central effects on appetite).
The obese subjects of this study were also hyperinsu-
linemic and insulin resistant compared with their lean
counterparts. It has been shown that cholinergic regula-
tion is an important part of meal-induced insulin release
(38). The M3 knockout mice mentioned above were re-
ported to have improved glucose tolerance despite a
blunted increase in serum insulin after oral glucose load
that was only partly explained by their leanness; in vitro
studies showed a lack of cholinergic stimulation of insulin
release from pancreatic islets of these mice (39). A genetic
variant of the M3 receptor has been associated with an
increased risk for developing type 2 diabetes in Pima
Indians (40). Atropine has been shown repeatedly to alter
meal-induced glucose increase in humans (38,41–43), as
was the case in the subjects studied here. One of these
studies (42) reported a greater postprandial attenuation of
insulin in obese compared with lean subjects. We report
for the ﬁrst time in this study that, while the alterations of
meal-induced insulin and glucose release by atropine were
largely comparable in lean and obese subjects, their atro-
pine-induced regulation of gut hormone release was mark-
edly different.
Insulin resistance, as quantiﬁed by HOMA and OGIS
indexes, was not signiﬁcantly correlated with ghrelin and
PYY changes induced by atropine or breakfast in this study
sample. In line with our data, it has been shown in lean but
insulin-resistant Pima Indians that postprandial early-
phase insulin release is inhibited by atropine but not to the
same extent as by pancreatic polypeptide, and it was
concluded that the hyperinsulinemia in this population
was not due to increased vagal input to the pancreatic
	-cell (43). Prolonged glucose infusion in lean healthy
humans resulted in vagally mediated compensatory in-
crease in C-peptide secretion but not in alterations of
hunger ratings or food intake (44). These data argue
against insulin resistance being the driving force of the
disturbed cholinergic control observed in this group of
obese subjects.
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DIABETES, VOL. 57, SEPTEMBER 2008 2337Taken together, the data presented here show that 1)i n
lean individuals the cholinergic system is involved in the
regulation of gut hormone release, 2) gut hormone release
is associated with subjective ratings of hunger and satiety,
and 3) this regulatory system is markedly impaired in
obese subjects. At present, however, it is not clear
whether this impaired regulation of gut hormone release
actually contributes to the impaired sensing of hunger and
satiety seen in these obese subjects and may actively
contribute to weight gain and/or hinder weight loss.
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